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The aim of this study was to determine the frequency of drug resistance and the clonality of genotype patterns in M. tuberculosis
clinical isolates from pediatric patients in Mexico (n = 90 patients from 19 states; time period—January 2002 to December 2003).
Pulmonarydiseasewasthemostfrequentclinicalmanifestation(71%).Childrenwithsystemictuberculosis(TB)weresigniﬁcantly
younger compared to patients with localized TB infections (mean 7.7 ± 6.2 years versus 15 ± 3.4 years P = 0.001). Resistance to
any anti-TB drug was detected in 24/90 (26.7%) of the isolates; 21/90 (23.3%) and 10/90 (11.1%) were resistant to Isoniazid and
Rifampicin,respectively,and10/90(11.1%)strainsweremultidrug-resistant(MDR).Spoligotypingproducedatotalof55diﬀerent
patterns; 12/55 corresponded to clustered isolates (n = 47, clustering rate of 52.2%), and 43/55 to unclustered isolates (19 patterns
were designated as orphan by the SITVIT2 database). Database comparison led to designation of 36 shared types (SITs); 32 SITs
(n = 65 isolates) matched a preexisting shared type in SITVIT2, whereas 4 SITs (n = 6 isolates) were newly created. Lineage
classiﬁcation based on principal genetic groups (PGG) revealed that 10% of the strains belonged to PGG1 (Bovis and Manu
lineages). Among PGG2/3 group, the most predominant clade was the Latin-American and Mediterranean (LAM) in 27.8%
of isolates, followed by Haarlem and T lineages. The number of single drug-resistant (DR) and multidrug-resistant (MDR-TB)
isolates in this study was similar to previously reported in studies from adult population with risk factors. No association between
the spoligotype, age, region, or resistance pattern was observed. However, contrary to a study on M. tuberculosis spoligotyping in
Acapulco city that characterized a single cluster of SIT19 corresponding to the EAI2-Manila lineage in 70 (26%) of patients, not
a single SIT19 isolate was found in our pediatric patient population. Neither did we ﬁnd any shared type belonging to the EAI
family which represents ancestral PGG1 strains within the M. tuberculosis complex. We conclude that the population structure of
pediatric TB in our setting is diﬀerent from the one prevailing in adult TB patient population of Guerrero.
1.Introduction
Although curable, tuberculosis (TB) remains a global public
health concern with a major impact in developing countries
[1]. Globally, approximately nine million new TB cases and
1.6 million deaths occur every year. The global epidemiology
of TB in children is limited; however, the World Health
Organization (WHO) estimates that one million cases
occurred in children, comprising up to 10% of the total TB
incidence [2–4]. Children rarely transmit the disease, and2 Tuberculosis Research and Treatment
thus contribute little to the maintenance of the TB epidemic
even though they make up a substantial proportion of the
global disease burden [5].
The increasing number of drug-resistant, and especially
multidrug-resistant (MDR: deﬁned as resistance to at least
isoniazid and rifampicin), cases is a serious concern for the
Global TB Control Program instituted by the WHO [6–9].
Treatment of drug-resistant TB is expensive and complex
because it necessitates the use of second-line drugs, which
are associated with a greater incidence of adverse events [10].
The true extent of drug resistance is unknown, but it is
estimated that the global proportion of resistance among all
cases is 4.8% (95% conﬁdence interval (CI) 4.6 to 6.0%),
with an estimated 489,000 cases of MDR-TB occurring
worldwidein2006.Itisthussuggestedthatresistancetoanti-
TB drugs may be increasing in some geographical areas, with
considerable variation between diﬀerent countries [11].
Mexico has a declining, but still moderate, incidence of
TB that is variable among states (WHO 2005). In 2007, the
reported incidence was 13.49 cases/100,000 individuals, with
a range of 2.35 to 35.34 cases/100,000 inhabitants and an
incidence rate of 5.077/100,000 in children under 19 years
of age (Indicadores Demogr´ aﬁcos 1990–2030 Consejo
CONAPO Sistema Nacional de Vigilancia Epidemiol´ ogica,
Direcci´ on General de Epidemiolog´ ıa, Secretaria de Salud).
Unfortunately,Mexico’ssurveillancesystemdoesnotprovide
an accurate estimation of the drug-resistant strains because
the diagnosis of TB is typically performed by direct acid fast
bacilli sputum smears. However, limited data from culture-
baseddrugsusceptibilitytestingin2008indicatethat2.4%of
cases are initially MDR-TB (http://www.cenavece.salud.gob
.mx/descargas/pdf/tuberculosis.pdf). There are now up to
479 reported cases of MDR-TB, seven of which were in
patients under 19 years of age and 47 that were likely
extensively drug-resistant TB (XDR-TB). A strain is consid-
ered XDR-TB if it is resistant to isoniazid, rifampicin, any
ﬂuoroquinolone and at least one of three injectable second-
line drugs (amikacin, kanamycin, or capreomycin); thus,
these cases are on the verge of being untreatable [12]. MDR-
TB and XDR-TB are among the greatest concerns in the
antibiotic resistance pandemic due to the high risk of death
[12, 13]. Furthermore, patients can remain infectious for
months or even years [14] and may spread MDR- or XDR-
TB. Consequently, early detection and an accurate record
of individuals the patient has had contact with, are critical
in arresting further transmission of the disease and for the
proper control of TB.
Study of TB molecular epidemiology through DNA ﬁn-
gerprinting is an important tool contributing to the under-
standing of the transmission and control of TB [15, 16].
PCR-based spacer oligonucleotide typing (spoligotyping)
based on the variability of the direct repeat (DR) locus in the
M. tuberculosis complex has emerged as a fast, reliable, and
cost-eﬀective alternative to the traditional IS6110 restriction
fragment length polymorphism (RFLP) for a ﬁrst-line geno-
typic screening of tubercle bacilli [17–19]. More recently,
this methodology has been used to provide support for
lineage-speciﬁc diﬀerences and global phylogeography of TB
in international databases [20]. In this context, we thought
it desirable to focus on pediatric TB since childhood TB is a
sentinel event, indicating the ongoing transmission of TB. In
addition, these patients are more likely to develop severe
cases and extrapulmonary diseases than adults. Unfortu-
nately, there is little information regarding the epidemiology
and resistance patterns to anti-TB drugs in children [6]. The
aimofthisstudywastodeterminethegenotypediversityand
theextentofdrugresistanceinM.tuberculosisclinicalisolates
from pediatric patients in Mexico.
2. Methods
2.1. Patients and Specimens. This study included a total of 90
Mycobacterium tuberculosis complex isolates, recruited from
patients who were 18 years of age or younger over a 2-year
period (January 2002 to December 2003) from 18 federal
States in Mexico (see Table S1 of Supplementary Material
available online at doi: 10.1155/2011/239042). Clinical spec-
imen were processes at the local laboratories for culture, fol-
lowed by identiﬁcation and drug susceptibility testing (DST)
performed at the mycobacteriology laboratory at Instituto
De Diagn´ ostico y Referencia de Epidemiol´ ogicos (InDRE)
in Mexico city. Isolates were characterized using several
biochemical tests: niacin and nitrate positivity; pyrazinami-
dase activity; negative for catalase activity at 68◦C[ 18]; in-
house PCR-RFLP of hsp65; determination of antimicrobial
resistance using the semiautomated radiometric BACTEC
460TB system according to the manufacturer’s instructions
(Becton Dickinson, Sparks, MD, USA), with following
critical concentrations: streptomycin (STM, 1.0 µg/mL),
rifampicin (RMP, 1.0µg/mL), isoniazid (INH, 0.1µg/mL),
pyrazinamide (PZA, 100µg/mL), and ethambutol (EMB,
5µg/mL). Basic demographic data was collected for each
patient using a standard questionnaire using the ﬁles pro-
vided at the local hospitals. The protocol was approved by
the Research and Ethics Committee of the Instituto Nacional
de Pediatria in Mexico City.
2.2. Spoligotyping and Database Comparison. Spoligotyping
was performed at the Immunology and Molecular Micro-
biology Program at the National Autonomous University of
Mexico on DNA extracted from heat inactivated cultures
using a previously described protocol [19]. Spoligotypes
in octal codes were entered in the SITVIT2 proprietary
database of the Pasteur Institute of Guadeloupe, which is an
updated version of the previously released SpolDB4 database
[20]. A Spoligotype International Type (SIT) number was
attributedtoeachpatternaccordingtotheSITVIT2database.
At the time of the present study, SITVIT2 contained more
than 3000 SITs with global genotyping information on
about 75,000 M. tuberculosis complex (MTC) clinical isolates
from 160 countries of origin. Worldwide distribution of
spoligotypes for all clustered isolates (SITs representing 2 or
more strains) was investigated using the SITVIT2 database
and recorded for countries and regions representing ≥5%
of a given SIT as compared to their total number in the
global database. The various macrogeographical regions
and subregions were deﬁned per UN speciﬁcations (http://
unstats.un.org/unsd/methods/m49/m49regin.htm). In thisTuberculosis Research and Treatment 3
Table 1: Characteristics of M. tuberculosis drug resistance to ﬁrst line antituberculosis drugs.
Number of drugs Number of isolates Resistance to antituberculosis drugs (no and %)
INH STM RMP PZA EMB
1 8 5 (23.8) 3 (21.2) — — —
2 6 6 (28.5) 2 (18.1) 2 (20.0) 1 (12.5) 1 (11.1)
3 5 5 (23.8) 2 (18.1) 3 (30.0) 2 (25.0) 3 (33.3)
4 1 1 (4.7) — 1 (10.0) 1 (12.5) 1 (11.1)
5 4 4 (19.0) 4 (36.3) 4 (40.0) 4 (50.0) 4 (44.1)
Global resistance 24 21 (23.3) 11 (12.2) 10 (11.1) 8 (8.8) 9 (10.0)
INH: Isoniazid, STM: Streptomycin, RMP: Rifampicin, PZA: Pyrazinamide, EMB: Ethambutol.
database, SIT (Spoligotype International Type) designates
spoligotyping shared by 2 or more patient isolates, as
opposed to “orphan” which designates patterns reported for
a single isolate. Major phylogenetic clades were assigned
according to signatures provided in SpolDB4, which deﬁned
62 genetic lineages/sublineages [20]. These include speciﬁc
signatures for various MTC members such as M. bovis, M.
caprae,M.microti,M.canetti,M.pinipedi,andM.africanum,
as well as rules deﬁning major lineages/sublineages for M.
tuberculosis sensu stricto; these include the Beijing clade,
the Central Asian (CAS) clade and 2 sublineages, the East
African-Indian (EAI) clade and 9 sublineages, the Haarlem
(H) clade and 3 sublineages, the Latin American-Medi-
terranean (LAM) clade and 12 sublineages, the ancestral
“Manu” family and 3 sublineages, the S clade, the IS6110-
low-banding X clade and 3 sublineages, and an ill-deﬁned T
cladewith5sublineages(aswellasfurtherwell-characterized
phylogeographical speciﬁcity for 8 additional spoligotype
signatures).
2.3. Distinction of “Ancient” versus “Modern” Lineages. We
also compared the overall repartition of isolates according
to major M. tuberculosis genotypic families by adding all the
sharedtypesforeachoftheindividualfamilydeﬁned(aswell
as the orphan strains), and further linked the information
obtained based on the lineage classiﬁcation to “ancient”
and “modern” lineages of tubercle bacilli as deﬁned by
principal genetic groups (PGGs) based on KatG463-gyrA95
polymorphism [21], inferred from the reported linking of
speciﬁc spoligotype patterns to PGG1, 2 or 3 [22–24].
2.4. Statistical Analyses. SPSS for Windows version 13.0 was
used for statistical analyses. Association between categor-
ical variables was assessed by Fisher’s exact test and the
Mann-Whitney U test was used to evaluate associations
between numerical variables. Diﬀerences between groups
were detected by univariate analyses and expressed as the
odds ratio (OR) with 95% conﬁdence intervals (95% CI).
Diﬀerences were considered to be signiﬁcant if values were
<0.05.
3. Results
3.1. Study Population. This study included a total of 90 M.
tuberculosis complex strains isolated from pediatric patients
in 18 federal States over a 2-year period (January 2002
to December 2003), which were subsequently referred to
the National Institute for Diagnostic and Epidemiological
Reference (InDRE) for identiﬁcation and drug susceptibility
testing.Theserepresentedbetween0.4and15.5%ofTBcases
in this age group as reported by the General Epidemiology
Division by those States during the study period. Detailed
informationonindividualstrainsobtainedduringthisinves-
tigation is summarized in Table S1. Information regarding
each strain includes year of isolation, spoligotype descrip-
tion, shared-type number, genotypic lineage, and drug sus-
ceptibility to ﬁrst-line drugs. Additional demographic and
clinical information includes pathological specimen, site of
infection, geographical origin, age, and sex of the patients.
3.2. Clinical Manifestations. M. tuberculosis was mostly iso-
lated from sputum samples (77%), mainly in patients with
localized TB. In contrast, patients with disseminated disease
were diagnosed by spinal ﬂuid (8%), gastric aspirates (4%),
urine (2%), pleural ﬂuid (1%), or tissue (8%). Male patients
(48) comprised 53% of the population; the mean age of all
was 13 ± 5y e a r s ,6 0 %w e r eb e t w e e n1 5a n d1 8y e a r so l d
and only 8% were under two years of age. Localized TB was
diagnosed in 76% of the cases and systemic TB diagnoses
corresponded to the remaining 24%. The disease frequently
presented as pulmonary TB (65 cases, 71.4%) and was
followed by meningeal in 8 cases (8.8%), disseminated in
5 cases (5.5%), miliary in 4 cases (4.4%), abdominal in 3
cases (3.3%), ganglionary in 3 cases (3.3%), urinary in 2
cases (2.2%), and pleural in 1 case (1.1%). Patients with
systemic TB were signiﬁcantly younger (7.7±6.2 years) than
children with localized TB (15 ± 3.4y e a r s ) ,P = 0.000. Of
this population, in 19 of the patients the presence of prior
underlying condition was not known. In 10/71 (14%) of the
patients, accompanying pathology was identiﬁed: 6 (8.4%)
were severely malnourished, 2 (2.8%) had a coinfection
with human immunodeﬁciency virus, 1 (1.4%) patient
harboring a SIT1/Beijing genotype had diabetes mellitus,
and 1 (1.4%) presented with alcoholism. The patients with
diabetes mellitus and alcoholism were 18 years of age. The
remaining 61 patients had no associated comorbidity.
3.3. Drug Resistance. As summarized in Table 1, M. tubercu-
losis isolate showed resistance to at least one anti-TB drug in
24/90 (26.7%) patients; 8 (8.8%) were resistant to a single
drug and 4 (4.4%) showed resistance to ﬁve ﬁrst-line TB4 Tuberculosis Research and Treatment
Table 2: Description of orphan strains (n = 19) and corresponding spoligotyping deﬁned lineages.
ISO number Year Strain Country of origin Spoligotype description Octal code Clade∗∗
MEX0120021C1209 2002 C1209 MEX 640033777777600 BOVIS
MEX0120021C121 2002 C121 MEX 517367636700771 Unk
MEX0120021C1262 2002 C1262 MEX 777767607540131 LAM4
MEX0120021C1365 2002 C1365 MEX 677767606740371 LAM8
MEX0120021C1677 2002 C1677 MEX 640033777777710 Unk
MEX0120021C1842 2002 C1842 MEX 731044606763771 Unk
MEX0120021C521 2002 C521 MEX 777777602003771 Unk
MEX0120021C672 2002 C672 MEX 410222000000031 Unk
MEX0120022C615 2002 C615 MEX 770346627740371 Unk
MEX0120022C890 2002 C890 MEX 777340004020771 H1
MEX0120023C111 2002 C111 MEX 711022103370371 Unk
MEX012002C1519 2002 C1519 MEX 676773777777710 Unk
MEX012002C164 2002 C164 MEX 777367626760771 T1
MEX012002C855 2002 C855 MEX 477777477403701 Unk
MEX0120031C1261 2003 C1261 MEX 700076777740271 X3
MEX0120031C1283 2003 C1283 MEX 777777607560531 LAM6
MEX0120031C54 2003 C54 MEX 674363777776000 BOVIS
MEX0120031C655 2003 C655 MEX 777367623540771 T1
MEX0120031C765 2003 C765 MEX 517367637760771 T1
∗∗Clade designations are according to SITVIT2 database. Unk: unknown patterns within major clades described in SITVIT2.
drugs. The greatest resistance was found against INH (23.3%
of cases) followed by RMP (11.1% of cases). Resistance to
RMP was always accompanied by INH-resistance leading to
10 (11.1%) cases of MDR-TB. Of 71 patients from whom
information was available, 14 patients had previous TB
treatment, and secondary resistance was documented in 7/14
(50%) patients in contrast with primary resistance found
in 14/57 (24.5%) patients without previous TB treatment
(P = 0.06).
3.4. Risk Factors. Bivariate analysis of risks identiﬁed pre-
vious treatment as a risk factor for developing resistant to
M. tuberculosis with an OR = 2.03 (95% CI 1.01 to 4.07,
P = 0.06). Although this result is not statistically signiﬁcant,
it is of clinical relevance. Furthermore, the risk increased
signiﬁcantly in MDR-TB cases with an OR = 5.08 (95%
CI 1.5 to 16.5, P = 0.001). We did not ﬁnd signiﬁcant
diﬀerences between age and the presence or not of drug-
resistant M. tuberculosis (resistant 13.7 ± 5.4 years versus
non resistant 13.1 ± 5.2y e a r s ,P = 0.4). Nevertheless,
age was a signiﬁcant factor (P = 0.005) in patients with
MDR-TB (16 ± 2.2 years) compared to patients with drug-
sensitive TB (12.9 ± 5.4 years). Drug-resistant isolates were
identiﬁed in 27.5% of patients with both localized and
disseminated disease (P = 0.44). Patients with MDR-TB
were less likely to present systemic TB although this was not
statistically signiﬁcant, (localized 13% versus systemic 4.5%,
P = 0.24). The prevalence of drug-resistant strains showed
variation between diﬀerent Mexican states. In seven of the
twelve states where drug resistance was documented, MDR-
TB strains were identiﬁed. Follow-up treatment (6 months
for pulmonary TB and 12 months for other clinical forms)
was documented in 65 (71%) patients; 6 of these patients
(9%) died, 2 (3%) stopped treatment, and 1 (1%) patient
reported treatment failure. In this group, the presence of
drug resistance or MDR did not contribute to the risk of
death.
3.5. Spoligotyping. Spoligotyping produced a total of 55 dif-
ferent patterns for the 90 isolates studied. The succinct anal-
yses obtained of the prevailing genotypes within this sub-
population as compared to the spoligotypes recorded in the
SITVIT2 database are summarized in Tables 2, 3,a n d4.
Nineteen patterns corresponded to orphan strains that were
unique among all the strains recorded in the SITVIT2
database (Table 2), as opposed to 36 patterns from 71
patients that corresponded to shared types (Table 3), that
is, an identical pattern shared by 2 or more patients
worldwide (within this study, or matching another strain in
the SITVIT2 database). As shown in Table 3 for the 36 SITs
recorded, a total of 32 SITs (containing 65 isolates) matched
a preexisting shared type in the SITVIT2 database, whereas
4 SITs (containing 6 isolates) were newly created either
within the present study or after a match with an orphan
in the database. Irrespective of the database comparison,
12 patterns corresponded to clusters in the present study
(Table 4, 12 clusters containing 47 isolates, 2–12 isolates per
cluster), accounting for a clustering rate of 52.2% (47/90).
However, no statistically signiﬁcant association between
spoligotype patterns, age, region, drug resistance, or HIV
serology was observed.
3.6. Distinction of “Ancient” versus “Modern” Lineages.
Spoligotyping results and clade deﬁnitions were linked to theTuberculosis Research and Treatment 5
Table 3: Description of M. tuberculosis complex shared types in pediatric patients (n = 90).
SIT Spoligotype description Octal number
Total (%)
in this
study
% in this
study versus
database
Clade
Clustered
versus
unique
patterns
1 000000000003771 1 (1.1) 0.02 Beijing Unique
3 000000007720771 1 (1.1) 1.09 H3 Unique
17 677737607760771 1 (1.1) 0.17 LAM2 Unique
20 677777607760771 1 (1.1) 0.14 LAM1 Unique
33 776177607760771 2 (2.2) 0.19 LAM3 Clustered
34 776377777760771 1 (1.1) 0.13 S Unique
42 777777607760771 12 (13.3) 0.44 LAM9 Clustered
47 777777774020771 4 (4.0) 0.32 H1 Clustered
49 777777777720731 2 (2.2) 1.46 H3 Clustered
50 777777777720771 3 (3.3) 0.11 H3 Clustered
53 777777777760771 9 (10.0) 0.18 T1 Clustered
70 700076777760671 3 (3.3) 2.59 X3 Clustered
81 777377607760771 1 (1.1) 3.23 LAM9 Unique
91 700036777760771 1 (1.1) 0.42 X3 Unique
92 700076777760771 1 (1.1) 0.25 X3 Unique
95 777777607560731 1 (1.1) 2.56 LAM6 Unique
119 777776777760771 4 (4.4) 0.39 X1 Clustered
130 776177607760731 1 (1.1) 1.1 LAM3 Unique
239 777777777760031 1 (1.1) 1.92 T1 Unique
373 777777767760771 1 (1.1) 1.75 T1 Unique
398 777777607760631 1 (1.1) 8.33 LAM4 Unique
450 777776770000000 1 (1.1) 1.19 Unique
804 477777777760771 1 (1.1) 5 T1 Unique
1166 777377777760771 1 (1.1) 2.63 T1 Unique
1193 777777677773771 2 (2.2) 50 Manu1 Clustered
1243 777377777720771 2 (2.2) 14.29 H3 Clustered
1277 777777207760771 1 (1.1) 4.55 LAM9 Unique
1626 777777776760771 1 (1.1) 12.5 T1 Unique
1711 677337607760771 1 (1.1) 25 LAM2 Unique
2188 777377777760731 1 (1.1) 25 T2 Unique
2337 777377774020771 1 (1.1) 16.67 H1 Unique
2496 777367777760771 1 (1.1) 7.14 T1 Unique
3079∗ 476363636756200 2 (2.2) 100 BOVIS Clustered
3080∗ 777377777763771 2 (2.2) 66.67 Manu2 Clustered
3089∗ 337777777760771 1 (1.1) 50 T1 Unique
3090∗ 677773777777600 1 (1.1) 50 BOVIS Unique
Shared types (SIT) followed by an asterisk indicate “newly created” shared types (n = 4) due to 2 or more strains belonging to an identical new pattern within
this study (SIT3079, SIT3080), or a unique strain from this study matching with another orphan in the database (SIT3089 matched an orphan from Peru;
SIT3090 matched an orphan from USA). Note that SIT3080 was created by 2 strains belonging to an identical pattern within this study that also matched an
orphan from Saudi Arabia.
Clade designations are according to SITVIT2 database. Unk: unknown patterns within major clades described in SITVIT2.
Clustered versus unique patterns; clustered strains correspond to a similar spoligotype pattern shared by 2 or more strains “within this study”; as opposed to
unique strains harboring a spoligotype pattern that does not match with another strain from this study. Unique strains matching a preexisting patterni nt h e
SITVIT2 database are classiﬁed as SITs, whereas in case of no match, they are designated as “orphan” (see Table 1).6 Tuberculosis Research and Treatment
Table 4: Description of shared types representing clustered strains and their worldwide distribution.
SIT (Clade), octal number spoligotype description Total (%)
in this study
% in this study
versus database
Distribution in
regions with
≥5% of a given SIT
Distribution in
countries with
≥5% of a given SIT
33 (LAM3), 776177607760771
2 (2.2) 0.19
AFRI-S 31.46,
AMER-S 21.68,
AMER-N 15.78,
EURO-S 13.36,
EURO-W 5.32
ZAF 31.46,
USA 15.39,
BRA 8.81,
ESP 8.62,
ARG 5.52,
PER 5.42
42 (LAM9), 777777607760771
12 (13.3) 0.44
AMER-S 28.25,
AMER-N 15.85,
EURO-S 12.11,
AFRI-N 10.44,
EURO-W 6.65
USA 14.44,
BRA 9.78,
MAR 8.58,
COL 7.45,
ITA 6.36
47 (H1), 777777774020771
4 (4.4) 0.32
AMER-N 21.20,
EURO-W 20.06,
EURO-S 13.73,
AMER-S 10.40,
EURO-E 8.37
USA 19.33,
AUT 10.24,
ITA 7.23,
BRA 5.85
49 (H3), 777777777720731
2 (2.2) 1.46
AMER-N 21.90,
EURO-N 21.17,
EURO-W 13.14,
AMER-S 12.41,
EURO-S 10.95,
AFRI-M 5.84
USA 18.98,
FIN 16.79,
PER 5.84,
AUT 5.11,
PRT 5.11,
FXX 5.11
50 (H3), 777777777720771
3 (3.3) 0.11
AMER-N 21.94,
AMER-S 15.88,
EURO-W 15.34,
EURO-S 12.62,
EURO-E 6.45,
AFRI-N 5.16
USA 21.33,
AUT 7.38,
ESP 6.59,
ITA 5.27
53 (T1), 777777777760771
9 (10.0) 0.18
AMER-N 19.55,
AMER-S 14.24,
EURO-W 12.62,
EURO-S 9.87,
ASIA-W 8.55,
AFRI-S 6.40
USA 17.05,
ZAF 6.26,
ITA 5.05
70 (X3), 700076777760671
3 (3.3) 2.59
AMER-N 68.10,
CARI 17.24,
AMER-S 5.17
USA 60.34,
MEX 7.76,
BHS 6.90,
HTI 6.90,
GUF 5.17
119 (X1), 777776777760771
4 (4.4) 0.39 AMER-N 70.10,
AFRI-S 14.02
USA 61.76,
ZAF 14.02,
MEX 7.65
1193 (Manu1), 777777677773771
2 (2.2) 50.00 ASIA-S 50.00,
AMER-N 50.00
MEX 50.00,
IND 50.00
1243 (H3), 777377777720771
2 (2.2) 14.29
EURO-S 35.71,
ASIA-W 21.43,
AMER-N 14.29,
ASIA-SE 7.14,
AMER-S 7.14,
EURO-W 7.14,
ASIA-E 7.14
ESP 28.57,
MEX 14.29,
TUR 14.29,
ITA 7.14,
NLD 7.14,
SAU 7.14,
TWN 7.14,
COL 7.14,
MYS 7.14
3079∗ (BOVIS), 476363636756200
2 (2.2) 100.00 AMER-N 100.00 MEX 100.00Tuberculosis Research and Treatment 7
Table 4: Continued.
SIT (Clade), octal number spoligotype description Total (%)
in this study
% in this study
versus database
Distribution in
regions with ≥5%
of a given SIT
Distribution in
countries with
≥5% of a given SIT
3080∗ (Manu2),777377777763771
2 (2.2) 66.67 AMER-N 66.67,
ASIA-W 33.33
MEX 66.67,
SAU 33.33
Worldwide distribution is reported for regions with ≥5% of a given SITs as compared to their total number in the SITVIT2 database. The deﬁnition of
macrogeographical regions and subregions (http://unstats.un.org/unsd/methods/m49/m49regin.htm) is according to the United Nations; Regions: AFRI
(Africa), AMER (Americas), ASIA (Asia), EURO (Europe), and OCE (Oceania), subdivided in: E (Eastern), M (Middle), C (Central), N (Northern), S
(Southern),SE(South-Eastern),andW(Western).Furthermore,CARIB(Caribbean)belongstoAmericas,whileOceaniaissubdividedin4subregions:AUST
(Australasia),MEL(Melanesia),MIC(Micronesia),andPOLY (Polynesia).Note thatinour classiﬁcationscheme, Russiahasbeenattributedanewsub-region
by itself (Northern Asia) instead of including it among rest of the Eastern Europe. It reﬂects its geographical localization as well as due to the similarity of
speciﬁc TB genotypes circulating in Russia (a majority of Beijing genotypes) with those prevalent in Central, Eastern, and South-Eastern Asia.
The 3 letter country codes are according to http://en.wikipedia.org/wiki/ISO 3166-1 alpha-3; countrywide distribution is only shown for SITs with ≥5% of a
given SITs as compared to their total number in the SITVIT2 database.
distribution of clinical isolates within the principal genetic
group PGG1 versus PGG2/3 (the latter being putatively
characterized by the lack of spacers 33–36), it was evident
that only 10/90 (11.1%) strains belonged to PGG1 (BOVIS,
Manu and Beijing/W lineages), the rest being classiﬁed as
evolutionary recent PGG2/3 strains. Indeed, LAM was the
most predominant clade (25/90 or 27.8% of the isolates,
including the major cluster composed of SIT42/LAM9
sublineage, n = 12/90 or 13.3% of the isolates), followed by
the Haarlem and T families.
4. Discussion
Our study aimed to estimate the genotype diversity and the
global prevalence of drug-resistant TB in pediatric patient
population. This is the ﬁrst report of resistance to primary
antimicrobial drugs in an exclusively pediatric Mexican
population. The extent of childhood TB is unknown and
is estimated that has a limited impact on the dynamics of
the TB epidemic; however, pediatric TB indicates recent
transmission of a disease that has not been previously treated
or diagnosed. Therefore, childhood TB can be a reﬂection on
the ineﬃciency of programs for the control of the disease.
In this study, a high frequency of primary antimicrobial
resistance was observed (1 out of every 4 isolates). Resistance
to INH alone or in combination with other anti-TB drugs
wasmostprevalent,withaglobalresistanceof23%,aﬁnding
which is higher than the 18% prevalence previously reported
in population based studies in Mexico [25, 26]. In this
respect, our observation is similar to prevalence of 29% to
56% reported in studies in Chiapas and Veracruz (Mexico)
for high-risk populations [27–29]. When the prevalence of
INH resistance is ≥4%, the use of a fourth drug (myambutol
or streptomycin) is recommended to ensure therapeutic suc-
cess; a standard that was adopted in Mexico in 2000 as part
of the TAES strategy—Norma oﬁcial Mexicana NOM-006-
SSA2-1993 para la prevenci´ on y control de la tuberculosis
para la atenci´ on primaria de la salud (http://www.salud.gob
.mx/unidades/cdi/nom/m006ssa23.html).
Importantly, the magnitude of RMP-resistance in our
study (11%) is higher than previously determined level in
Mexico (3%). Resistance to RMP was always accompanied
by INH-resistance leading to 10 (11.1%) cases of MDR-TB.
Although because of the small number of isolates studied,
this high rate of MDR-TB observed (11%) might not reﬂect
the exact rates of drug resistance in this age group, this
ﬁnding is relevant because RMP and INH are among the
most important 1st-line drugs involved both in the TAES
strategy (see above) as well as in the WHO-recommended
Directly Observed Therapy—Short Course (DOTS) strat-
egy (http://www.who.int/tb/dots/en/index.html). MDR-TB
is linked to a greater probability of therapeutic failure and
a lower survival rate, with a calculated relative risk for
mortality of 2.5 (95% CI 1.02 to 6.16, P = 0.04) [29]. The
occurrence of MDR-TB has logistical implications in the
necessity of tests for drug resistance and the use of second-
line drugs.
Because of the limited number of patients in our study,
it is diﬃcult to compare the mortality of MDR-TB, which
is lower than reported in other national studies [30, 31].
Distribution clusters of any kind were not observed for
resistant M. tuberculosis isolates, however, 20% of patients
were retreated due to therapeutic failure in our study, a
ﬁnding which is in agreement with previous reports showing
that previous TB treatment is a predictor for resistance [32,
33]. These observations stress the importance of performing
periodical population studies to determine the prevalence
and incidence of drug-resistant M. tuberculosis and to
establish the most eﬀective strategies for the control TB.
Spoligotyping of the clinical isolates showed the great
diversity of circulating genotypes, with 55 diﬀerent patterns
which is common in countries with endemic. The spolig-
otypes were not associated with the geographical location
of the patient or the presence of resistance to one or more
antimicrobial drugs. The worldwide distribution of predom-
inant shared types and lineages from our study underlined
thatmanyofthegenotypesencounteredinthepediatricpop-
ulation were the ones most frequently represented in Mexico
and neighboring USA, the rest being essentially shared with
other Latin American and Caribbean neighbors (Table 4).
Thus with the exception of ubiquitous spoligotypes (such
as the T clade found throughout the world), the patients
in our study mainly harboured M. tuberculosis spoligotypes
prevailing in the Americas, and mostly belonging to evolu-
tionary recent PGG2/3 lineages. However, the “T” genotype
does not represent a clade in a strict evolutionary sense8 Tuberculosis Research and Treatment
since it was deﬁned by default to include strains that may
not be classiﬁed in one of the established genotypic lineages
with well-established phylogeographical speciﬁcity such as
theHaarlem,LAM,CAS,andEAIlineages[20].Interestingly,
out of the 12 sublineages reported worldwide for the LAM
clade [20], a total of 6 sublineages were present in our 2-year
recruitment. Last but not least, the near absence of Beijing
genotype (n = 1) in this study is noteworthy and none
were associated with 2 HIV patients (one of the HIV patients
harbored a T1 lineage strain).
A remarkable feature of our study is the presence of a few
ancestralManulineagestrains(n=4/90or4.4%)asclustered
strains within our study sample. The “Manu” lineage was
initially described as a new family from India in 2004 [34],
and later similar strains in small numbers were reported
in a study from Madagascar [35]. Soon afterwards, it was
tentatively subdivided into Manu-1 (deletion of spacer 34),
Manu-2 (deletion of spacers 33-34), and Manu-3 (deletion
of spacers 34–36) sublineages, and it was suggested that it
could represent an ancestral clone of principal genetic group
1 strains [20]. Manu lineage strains were recently reported
from Saudi Arabia [36], Tunisia [37] ,a n dm o r er e c e n t l yi na
study from Egypt where it represented as high as 27% of all
isolates [38].
Contrary to a recent study on M. tuberculosis spolig-
otyping in Acapulco city that showed a single cluster of
70 (26%) patients harboring a single spoligotype (SIT19)
corresponding to the EAI2-Manila lineage [39], we did not
ﬁnd a single SIT19 isolate in the pediatric patient population
of our study. Neither did we ﬁnd any shared type belonging
to the EAI family which represents ancestral PGG1 strains
within the M. tuberculosis complex [20]. We therefore
conclude that the population structure of pediatric TB in
our setting is entirely diﬀerent from the one prevailing in
adult TB patient population of Guerrero with evidence of
an ongoing transmission with ancestral EAI2-Manila lineage
[39].Inconclusion,ourstudyshowsthatTBamongpediatric
patients in Mexico is essentially caused by evolutionary
recentgenotypescharacteristicoftheAmericas.However,the
presence of the ancestral Manu lineage strains, supposed to
be a missing link of the split between ancestral and modern
tubercle bacilli during M. tuberculosis evolution [38], should
be further investigated within larger datasets to know its
arrival in Mexico. Lastly, the clustering rate observed in
our study (52.2%) is certainly higher than expected since
further diﬀerentiation of spoligotyping deﬁned clusters was
not systematically performed using secondary markers such
as MIRU-VNTRs [40], which will be necessary in future
studies to draw epidemiological conclusions.
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